
    
      Study CC-122-DLBCL-001 is a Phase 1b dose escalation and expansion clinical study of CC 122,
      CC-223 and CC-292 administered orally as doublets with or without rituximab, in subjects with
      relapsed/refractory DLBCL who have failed standard therapy.

      In expansion phase, selected combination will be administered to lenalidomide na√Øve FL
      subjects and lenalidomide exposed FL subjects in addition to relapsed/refractory DLBCL
      subjects.
    
  